Teleflex Incorporated (NYSE:TFX), a leading global provider of medical devices for critical care and surgery, has announced it has received FDA 510(k) clearance to market its ARROW® NextStep® Retrograde Femoral Length Dialysis Catheters. Designed for clinician ease of insertion and sustained high flow rates, the ARROW NextStep Retrograde Femoral Length Catheters further strengthen the NextStep Hemodialysis Catheter portfolio.

“Providing clinicians with the ARROW NextStep Femoral Length Catheters continues a series of new product introductions that demonstrates our commitment to enhance patient outcomes and improve ease of use for clinicians,” said Linda Beneze, President and General Manager, Specialty Division. “We are proud to add the ARROW NextStep Retrograde Femoral Length Catheter to our portfolio.” The ARROW NextStep Retrograde Hemodialysis Catheter is the first of its kind designed to take better advantage of the blood flow dynamics within the heart through its unique reversed port configuration, where the venous port resides in the superior vena cava and the arterial port in the right atrium, resulting in reduced recirculation and high flow rates. The unique NextStep Tip is designed for smooth, over-the-wire transitions during catheter insertions and exchanges.

About Teleflex Incorporated Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 11,700 people worldwide and serves healthcare providers in more than 140 countries. Additional information about Teleflex can be obtained from the company’s website at teleflex.com.